Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: Mirror Image who wrote (1563)	11/18/2015 5:37:37 PM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

MI, your experience and reasons for being here "mirror" mine. The slow sales progress of Vitaros does not require some wildcard or approval. The company seems pretty confident about V-US. If and when action occurs by the FDA, assuming the FDA does not balk this time, there should be increased outside interest...I think in buying the company.

To: Mirror Image who wrote (1563)	11/18/2015 6:36:30 PM
From: phoenix_rising	Respond to of 2026

Nice post MI. There are 2 reasons I am still in: 1, the fundamentals keep getting better and better (albeit much slower than I had anticipated) and this is not reflected in the share price. 2, I have too many bloody shares to get rid of easily! :P I expect there to be the usual end of year selling pressure which may even take us <$1 again like last year, then the January recovery. If they can get some sort of news out about Fis in January/February, then fantastic.